Table 3.

The importance of issues related to biosimilars in professional environments (n = 206).

Statement	Important/Extremely Important	Selected as Being in the Three Most Important Statements
Tracking safety events with biosimilars	99%	49%
Access to information on studies comparing biosimilars with reference biologics	96%	54%
Establish reasonable and scientifically justified approach to interchangeability and automatic substitution	93%	53%
Physician authority to decide on the most suitable biologic for each patient	89%	47%
Knowledge about biosimilars among interdisciplinary colleagues	86%	24%
Preparing (educating about biosimilars, which includes patients) to integrate biosimilars into clinical practice	84%	18%
Switching between reference biologics and biosimilars	74%	19%
Naming conventions for biosimilars (unique vs. same non-proprietary names)	74%	16%
Tender policy with preference for Russian manufacturers	54%	19%

Data were extracted from question 11 of the questionnaire (see Survey Questionnaire 1).